不同Ki67表达的浸润性乳腺癌临床特征分析
|
摘要
目的对比分析不同Ki67表达的浸润性乳腺癌的临床特征,探讨Ki67与各预后参数的关系。方法回顾性分析2015年1月至2017年12月期间行手术治疗的浸润性乳腺癌患者315例,根据Ki67表达高低分组,分为低表达组(Ki67≤14%)及高表达组(Ki67>14%),其中低表达组178例,高表达组137例。对两组患者的各预后参数进行记录、总结,包括肿物大小、转移淋巴结情况、组织学分级、ER表达、PR表达、HER-2表达及分子分型情况,分析上述参数在两组中的差异。结果两组患者的淋巴结转移情况对比差异没有统计学意义(P>0.05),两组患者的肿瘤大小、组织学分级、ER表达、PR表达、HER-2表达及分子分型情况方面存在统计学差异(P<0.05)。结论不同Ki67表达的浸润性乳腺癌临床特征具有一定差异。Ki67可以在浸润性乳腺癌中作为判断预后的指标,并有助于治疗决策的制定。
Objective To compare the clinical features of invasive breast cancer with different Ki67 expression and to explore the relationship between Ki67 expression and various prognostic parameters. Methods Totally 315 patients with invasive breast cancer, who underwent surgery in our hospital, were enrolled. According to the Ki67 expression level, they were divided into low expression group(Ki67≤14%) and high expression group(Ki67>14%). The prognostic parameters of the two groups were recorded and summarized, including tumor size, lymph node metastasis, histological grade, ER expression, PR expression, HER-2 expression and molecular subtype. Results There was no significant difference in lymph node metastasis between the two groups(P>0.05). There were significant differences on tumor size, histological grade, ER expression, PR expression, HER-2 expression and molecular subtype(P<0.05). Conclusion The clinical features of invasive breast cancer with different Ki67 expression are different. Ki67 can be used in invasive breast cancer as an indicator to obtain prognostic information and may help for therapeutic decisions.
Objective To compare the clinical features of invasive breast cancer with different Ki67 expression and to explore the relationship between Ki67 expression and various prognostic parameters. Methods Totally 315 patients with invasive breast cancer, who underwent surgery in our hospital, were enrolled. According to the Ki67 expression level, they were divided into low expression group(Ki67≤14%) and high expression group(Ki67>14%). The prognostic parameters of the two groups were recorded and summarized, including tumor size, lymph node metastasis, histological grade, ER expression, PR expression, HER-2 expression and molecular subtype. Results There was no significant difference in lymph node metastasis between the two groups(P>0.05). There were significant differences on tumor size, histological grade, ER expression, PR expression, HER-2 expression and molecular subtype(P<0.05). Conclusion The clinical features of invasive breast cancer with different Ki67 expression are different. Ki67 can be used in invasive breast cancer as an indicator to obtain prognostic information and may help for therapeutic decisions.
引文
[1] Hu Y, Gu R, Zhao J, et al. Prognostic significance of Ki67 in Chinese women diagnosed with ER+/HER2- breast cancers by the 2015 St. Gallen consensus classification[J]. BMC cancer, 2017, 17(1):28.
[2] Elkablawy MA, Albasri AM, Mohammed RA, et al. Ki67 expression in breast cancer: Correlation with prognostic markers and clinicopathological parameters in Saudi patients[J]. Saudi Med J, 2016, 37(2):137-141.
[3] Gallardo A, Garcia-Valdecasas B, Murata P, et al. Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis[J]. Breast Cancer Res Treat, 2018, 167(1): 31-37.
[4] Healey MA, Hirko KA, Beck AH, et al. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses’ Health Study[J]. Breast Cancer Res Treat, 2017, 166(2): 613-622.
[5] Ahmed ST, Ahmed AM, Musa DH, et al. Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas[J]. Asian Pac J Cancer Prev, 2018, 19(4): 955-959.
[6] Yao DJ, Qiao S, Zhang Y, et al. Correlation between expression of LRP16, Ki67 and EGFR and breast cancer clinical pathologic factors and prognosis[J]. Eur Rev Med Pharmacol Sci, 2017, 21(3 Suppl): 47-51.
[7] Haroon S, Hashmi AA, Khurshid A, et al. Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients[J]. Asian Pac J Cancer Prev, 2013, 14(7): 4353-4358.
[8] Martins SF, Amorim R, Mota SC, et al. Ki-67 expression in CRC lymph node metastasis does not predict survival[J]. Biomed Res Int, 2015, 2015:1-13.
[9] Li F, Wu S, Zhou J, et al. Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study[J]. PloS One, 2014, 9(2): e87264.
[10] Matsubara N, Mukai H, Itoh K, et al. Prognostic impact of Ki-67 overexpression in subgroups categorized according to St. Gallen with early stage breast cancer[J]. Oncology, 2011, 81(5-6): 345-352.
[11] Mandó P, Rizzo M, de la Puente CP, et al. High histologic grade and high Ki-67 expression predict phenotypic alterations in node metastasis in primary breast cancers[J]. J Breast Cancer, 2017, 20(2): 170-175.
[12] Madani SH, Payandeh M, Sadeghi M, et al. The correlation between Ki-67 with other prognostic factors in breast cancer: A study in Iranian patients[J]. Indian J Med Paediatr Oncol, 2016, 37(2): 95-99.
[13] Guy N, Michel K, Abdon M, et al. Expression of Ki-67 and Prognosis of Breast Invasive Carcinoma in Congolese Women[J]. Cancer Res, 2018, 3(1): 1-9.
[14] Inwald EC, Klinkhammer-Schalke M, Hofst?dter F, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry[J]. Breast Cancer Res Treat, 2013, 139(2): 539-552.
[15] Sheikhpour R, Poorhosseini F. Relation between Estrogen and Progesterone receptor status with p53, Ki67 and Her-2 markers in patients with breast cancer[J]. IJBC, 2016, 8(4): 93-97.
[16] Zhou H, Wang H, Yu G, et al. Synergistic inhibitory effects of an engineered antibodylike molecule ATFFc and trastuzumab on tumor growth and invasion in a human breast cancer xenograft mouse model[J]. Oncol Lett, 2017, 14(5): 5189-5196.
[17] Gao S, Ge A, Xu S, et al. PSAT1 is regulated by ATF4 and enhances cell proliferation via the GSK3β/β-catenin/cyclin D1 signaling pathway in ER-negative breast cancer[J]. J Exp Clin Cancer Res, 2017, 36(1): 179.
[18] Wu F, Huang W, Chen K, et al. Negative progesterone receptor status is an adverse prognostic factor for luminal B breast cancer[J]. Int J Clin Exp Pathol, 2017, 10(2): 901-911.
[19] Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease[J]. Nat Rev Clin Oncol, 2016, 13(11): 674-690.
[20] Singh SK, Singh S, Lillard Jr JW, et al. Drug delivery approaches for breast cancer[J]. Int J Nanomed, 2017, 12: 6205-6218.
[21] Bareche Y, Venet D, Ignatiadis M, et al. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis[J]. Ann Oncol, 2018, 29(4): 895-902.
[2] Elkablawy MA, Albasri AM, Mohammed RA, et al. Ki67 expression in breast cancer: Correlation with prognostic markers and clinicopathological parameters in Saudi patients[J]. Saudi Med J, 2016, 37(2):137-141.
[3] Gallardo A, Garcia-Valdecasas B, Murata P, et al. Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis[J]. Breast Cancer Res Treat, 2018, 167(1): 31-37.
[4] Healey MA, Hirko KA, Beck AH, et al. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses’ Health Study[J]. Breast Cancer Res Treat, 2017, 166(2): 613-622.
[5] Ahmed ST, Ahmed AM, Musa DH, et al. Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas[J]. Asian Pac J Cancer Prev, 2018, 19(4): 955-959.
[6] Yao DJ, Qiao S, Zhang Y, et al. Correlation between expression of LRP16, Ki67 and EGFR and breast cancer clinical pathologic factors and prognosis[J]. Eur Rev Med Pharmacol Sci, 2017, 21(3 Suppl): 47-51.
[7] Haroon S, Hashmi AA, Khurshid A, et al. Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients[J]. Asian Pac J Cancer Prev, 2013, 14(7): 4353-4358.
[8] Martins SF, Amorim R, Mota SC, et al. Ki-67 expression in CRC lymph node metastasis does not predict survival[J]. Biomed Res Int, 2015, 2015:1-13.
[9] Li F, Wu S, Zhou J, et al. Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study[J]. PloS One, 2014, 9(2): e87264.
[10] Matsubara N, Mukai H, Itoh K, et al. Prognostic impact of Ki-67 overexpression in subgroups categorized according to St. Gallen with early stage breast cancer[J]. Oncology, 2011, 81(5-6): 345-352.
[11] Mandó P, Rizzo M, de la Puente CP, et al. High histologic grade and high Ki-67 expression predict phenotypic alterations in node metastasis in primary breast cancers[J]. J Breast Cancer, 2017, 20(2): 170-175.
[12] Madani SH, Payandeh M, Sadeghi M, et al. The correlation between Ki-67 with other prognostic factors in breast cancer: A study in Iranian patients[J]. Indian J Med Paediatr Oncol, 2016, 37(2): 95-99.
[13] Guy N, Michel K, Abdon M, et al. Expression of Ki-67 and Prognosis of Breast Invasive Carcinoma in Congolese Women[J]. Cancer Res, 2018, 3(1): 1-9.
[14] Inwald EC, Klinkhammer-Schalke M, Hofst?dter F, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry[J]. Breast Cancer Res Treat, 2013, 139(2): 539-552.
[15] Sheikhpour R, Poorhosseini F. Relation between Estrogen and Progesterone receptor status with p53, Ki67 and Her-2 markers in patients with breast cancer[J]. IJBC, 2016, 8(4): 93-97.
[16] Zhou H, Wang H, Yu G, et al. Synergistic inhibitory effects of an engineered antibodylike molecule ATFFc and trastuzumab on tumor growth and invasion in a human breast cancer xenograft mouse model[J]. Oncol Lett, 2017, 14(5): 5189-5196.
[17] Gao S, Ge A, Xu S, et al. PSAT1 is regulated by ATF4 and enhances cell proliferation via the GSK3β/β-catenin/cyclin D1 signaling pathway in ER-negative breast cancer[J]. J Exp Clin Cancer Res, 2017, 36(1): 179.
[18] Wu F, Huang W, Chen K, et al. Negative progesterone receptor status is an adverse prognostic factor for luminal B breast cancer[J]. Int J Clin Exp Pathol, 2017, 10(2): 901-911.
[19] Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease[J]. Nat Rev Clin Oncol, 2016, 13(11): 674-690.
[20] Singh SK, Singh S, Lillard Jr JW, et al. Drug delivery approaches for breast cancer[J]. Int J Nanomed, 2017, 12: 6205-6218.
[21] Bareche Y, Venet D, Ignatiadis M, et al. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis[J]. Ann Oncol, 2018, 29(4): 895-902.